We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Paper-Based Test Monitors Liver Damage

By LabMedica International staff writers
Posted on 11 Oct 2012
A postage stamp-sized, paper-based device could provide a simple and reliable way to monitor for liver damage.

The paper-based microfluidic device is inexpensive and can be employed at the point of contact to test aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels concurrently, giving doctors near real time feedback and thus allowing them to make treatment plans, if necessary, on the spot. More...


Scientists at the Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) constructed the device using layers of patterned paper and a plasma separation membrane. A hole in the lamination allows for a finger stick or pipetted drop of whole blood or serum to be applied to the plasma separation membrane. The blood then wicks into the layers of paper, and through the microfluidic channels travels to separate zones for testing AST and ALT.

Jason Rolland, PhD, Senior Director of Research at Diagnostics for All (DFA; Cambridge, MA, USA) said, “A drop of blood is applied to the device and the activity of the enzymes present in the blood sample leads to changes in levels of specific dyes present in the paper zones. This gives rise to color changes that can be compared against a visual read guide and correspond to a concentration range for each of the enzymes." The test takes about 15 minutes to perform. The color changes, for example, from shades of blue to shades of pink, when increasing levels of AST are detected in the blood. In rigorous clinical tests using 223 whole blood and serum specimens from the paper-based test performed at greater than 90% accuracy compared against the gold standard automated platform test.


Additionally, the device could be used as a "triage test" in developed or developing nations to quickly and inexpensively rule out the need for automated laboratory testing. For example, if blood tested with the device shows that the liver enzymes fall below a certain threshold, more expensive testing could be avoided, saving healthcare costs and clinical resources. Nira Pollock, MD, PhD, the co-lead author said, “The next stage for the device is to test it in the field. We are working for a preliminary field study of the paper-based test in Ho Chi Minh City, Vietnam.” The study was published on September 19, 2012, in the journal Science Translational Medicine.

Related Links:
Beth Israel Deaconess Medical Center
Diagnostics For All


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.